Skip to main content
. 2022 May 26;61(1):85. doi: 10.3892/ijo.2022.5375

Figure 3.

Figure 3

Expression of STAT3 and p-STAT3 in human primary GC tissues. (A) Flow diagram presenting the study scheme using human primary tumors of GC patients who were treated with neoadjuvant chemotherapy/chemoradiation following as curative resection. (B) The proportion of p-STAT3-positive cancer cells in immunohistochemistry for primary GC tumors according to the responsiveness for neoadjuvant therapy. Representative image (magnification, ×200) for p-STAT staining and table showing the association between clinicopathological factors and the responsiveness to neoadjuvant therapy. These data were analyzed using the Chi-squared test. (C) Flow diagram presenting the study scheme using the public transcriptome dataset (GES62254) for human primary samples. (D) The correlation between STAT3 pathway gene set and stromal gene score, CCL2, CXCL1, IL-6, and CXCL8 expression in GSE62254 dataset. (E) Survival differences according to the expression of STAT3 pathway gene set in the GSE62254 dataset. CCL2, C-C motif chemokine ligand 2; GC, gastric cancer; IL-6, interleukin-6; STAT3, signal transducer and activator of transcription 3.